Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 22, 2014, Pages 9961-9966

  Ye, Yuan Xin ^a   Zhou, Juan ^a   Zhou, Yan Hong ^a   Zhou, Yi ^a   Song, Xing Bo ^a   Wang, Jun ^a   Lin, Li ^a   Ying, Bin Wu ^a   Lu, Xiao Jun ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Acute lymphoblastic leukemia; BCR ABL fusion gene; Chronic myeloid leukemia

Indexed keywords

BCR ABL PROTEIN; BENZAMIDE DERIVATIVE; IMATINIB; MESSENGER RNA; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADOLESCENT; ADULT; BLAST CRISIS; CANCER STAGING; CASE CONTROL STUDY; CHROMOSOME BREAKAGE; COMPARATIVE STUDY; DRUG RESISTANCE; FEMALE; FOLLOW UP; GENETICS; HUMAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; YOUNG ADULT;

ADOLESCENT; ADULT; BENZAMIDES; BLAST CRISIS; CASE-CONTROL STUDIES; CHROMOSOME BREAKPOINTS; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASM STAGING; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; YOUNG ADULT;

EID: 84921502754     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.22.9961     Document Type: Article

References (36)

1. Al-Seraihy AS, Owaidah TM, Ayas M, et al (2009). Clinical characteristics and outcome of children with biphenotypic acute leukemia. Haematologica, 94, 1682-90.
2. Awan T, Iqbal Z, Aleem A, et al (2012). Five most common prognostically important fusion oncogenes are detected in the majority of Pakistani pediatric acute lymphoblastic leukemia patients and are strongly associated with disease biology and treatment outcome. Asian Pac J Cancer Prev, 13, 5469-75.
3. Bhatia P, Binota J, Varma N, et al (2012). A study on the expression of BCR-ABL transcript in mixed phenotype acute leukemia (MPAL) cases using the reverse transcriptase polymerase reaction assay (RT-PCR) and its correlation with hematological remission status post initial induction therapy. Mediterr J Hematol Infect Dis, 4, 2012024.
4. Cetin Z, Yakut S, Karadogan I, et al (2012). Aberrations of chromosomes 9 and 22 in acute lymphoblastic leukemia cases detected by ES-fluorescence in situ hybridization. Genet Test Mol Biomarkers, 16, 318-23.
5. Cho YJ, Zhang B, Kaartinen V, et al (2005). Generation of rac3 null mutant mice: role of Rac3 in Bcr/Abl-caused lymphoblastic leukemia. Mol Cell Biol, 25, 5777-85.
6. Chomel JC, Sorel N, Guilhot J, et al (2012). BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia. Blood, 119, 2964-65; author reply 2965-66.
7. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al (2009). A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol, 10, 125-34.
8. Druker BJ, Guilhot F, O'Brien SG, et al (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 355, 2408-17.
9. Ernst T, Hochhaus A (2012). Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression. Semin Oncol, 39, 58-66.
10. Fausel C (2007). Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm, 64, 9-15.
11. Gabert J, Beillard E, van der Velden VH, et al (2003). Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe against cancer program. Leukemia, 17, 2318-57.
12. Gokbuget N, Stanze D, Beck J, et al (2012). Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood, 120, 2032-41.
13. Hanfstein B, Muller MC, Hehlmann R, et al (2012). Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia, 26, 2096-102.
14. Hehlmann R, Hochhaus A, Baccarani M (2007). Chronic myeloid leukaemia. Lancet, 370, 342-50.
15. Hunger SP (2011). Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia. Hematology Am Soc Hematol Educ Program, 2011, 361-5.
16. Killick S, Matutes E, Powles RL, et al (1999). Outcome of biphenotypic acute leukemia. Haematologica, 84, 699-706.
17. Lee KH, Lee JH, Choi SJ, et al (2005). Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia, 19, 1509-16.
18. Li Y, Zou D, Zhao Y, et al (2010). Clinical characteristics and outcomes of adults with Philadelphia chromosome positive and/or bcr-abl positive acute lymphoblastic leukemia: a single center study from China. Leuk Lymphoma, 51, 488-96.
19. Lu X, Song X, Ye Y, et al (2011). Quantitative detection of BCR-ABL fusion gene and its application in monitoring chronic myeloid leukemia treatment. Mol Biol Rep, 38, 3101-5.
20. Marin D, Ibrahim AR, Lucas C, et al (2012). Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol, 30, 232-8.
21. Matutes E, Pickl WF, Van't Veer M, et al (2011). Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood, 117, 3163-71.
22. Mizuta S, Matsuo K, Maeda T, et al (2012). Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR-ABL-positive ALL. Blood Cancer J, 2, 72.
23. Moorman AV, Harrison CJ, Buck GA, et al (2007). Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the medical research council (MRC) UKALLXII/Eastern cooperative oncology group (ECOG) 2993 trial. Blood, 109, 3189-97.
24. Mu Q, Ma Q, Wang Y, et al (2012). Cytogenetic profile of 1, 863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population. Ann Hematol, 91, 1065-72.
25. Mulloy JC, Cancelas JA, Filippi MD, et al (2010). Rho GTPases in hematopoiesis and hemopathies. Blood, 115, 936-47.
26. Ohanian M, Cortes J, Kantarjian H, Jabbour E (2012). Tyrosine kinase inhibitors in acute and chronic leukemias. Expert Opin Pharmacother, 13, 927-38.
27. Ohsaka A, Shiina S, Kobayashi M, et al (2002). Philadelphia chromosome-positive chronic myeloid leukemia expressing p190 (BCR-ABL). Intern Med, 41, 1183-7.
28. Press RD, Galderisi C, Yang R, et al (2007). A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res, 13, 6136-43.
29. Sabir N, Iqbal Z, Aleem A, et al (2012). Prognostically significant fusion oncogenes in Pakistani patients with adult acute lymphoblastic leukemia and their association with disease biology and outcome. Asian Pac J Cancer Prev, 13, 3349-55.
30. Soheila K, Hamid A, Farid Z, et al (2013). Comparison of univariate and multivariate gene set analysis in acute lymphoblastic leukemia. Asian Pac J Cancer Prev, 14, 1629-33.
31. Tripathi AK, Kumar A, Ramaswamy A (2011). Total Leukocyte counts and the requirement of dose reduction due to cytopenias as prognostic indicators affecting response to imatinib in chronic myeloid leukemia. Indian J Hematol Blood Transfus, 27, 7-13.
32. Uchida N, Hanawa H, Dan K, et al (2009). Leukemogenesis of b2a2-type p210 BCR/ABL in a bone marrow transplantation mouse model using a lentiviral vector. J Nippon Med Sch, 76, 134-47.
33. Wang Y, Gu M, Mi Y, et al (2011). Clinical characteristics and outcomes of mixed phenotype acute leukemia with Philadelphia chromosome positive and/or bcr-abl positive in adult. Int J Hematol, 94, 552-5.
34. Weinberg OK, Arber DA (2010). Mixed-phenotype acute leukemia: historical overview and a new definition. Leukemia, 24, 1844-51.
35. Yanada M, Takeuchi J, Sugiura I, et al (2008). Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Haematologica, 93, 287-90.
36. Yeung DT, Hughes TP (2012). Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia. Crit Rev Oncog, 17, 17-30.